# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Booker T. Washington (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI017-SYN-TD
- Date: 1915-05-04
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorraine Whitfield, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Reason for visit

Primary care visit for headaches, fatigue, and a very high blood pressure. **S**

## Historical basis

- Booker T. Washington was born into slavery on the James Burroughs plantation in Franklin County, Virginia, in 1856; the National Park Service timeline gives the date as April 5, 1856. **D**
- Washington wrote in Up from Slavery (1901) that he was not sure of the exact date of his birth and estimated the year as 1858 or 1859; the April 5, 1856 date traces to a report by his brother John after his death and was adopted by the Tuskegee trustees. **D**
- After emancipation in 1865 Washington moved with his mother, Jane, and his family to Malden, West Virginia, where he worked in the salt and coal mines; a National Park Service release gives his mother's death as 1876. **D**
- Washington opened Tuskegee Institute in Tuskegee, Alabama, on July 4, 1881, at age 25, and led it for the rest of his life; in March 1915 he sponsored National Negro Health Week. **D**
- In 1911 Washington was beaten in New York City and received two large gashes in his head and a torn ear, recovering without apparent sequelae; he had chronic indigestion, especially when traveling, and spent several days in 1911 at the Battle Creek Sanitarium. **D**

5 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- Frontal headaches every week or so, palpitations, and fatigue are cutting into his workday. **S**
- Worried about blurred reading vision and getting up at night to urinate. **S**
- Wants a plan that fits a heavy travel schedule. **S**

## Strengths and supports

- Supports: spouse, adult children, and long-time colleagues who urged him to be seen **S**

## Medications and allergies

- Amlodipine 10 mg oral tablet, one tablet by mouth daily **S**
- Losartan 50 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- 1911: Assault in New York City with two large scalp lacerations and a torn ear; recovered without apparent sequelae **D** (CLM-0005)
- 1911: Chronic indigestion, worse when traveling; several days of treatment at the Battle Creek Sanitarium in 1911 **D** (CLM-0005)

## Procedures and immunizations

- 1915-05-04 to 1915-05-04: 12-lead electrocardiogram: sinus rhythm with left ventricular hypertrophy by voltage **S**
- 1915-05-04 to 1915-05-04: Dilated funduscopic examination: arteriolar narrowing and arteriovenous nicking in both eyes; no hemorrhages, exudates, or papilledema **S**
- 1914-10-20: Influenza vaccine, 1914-1915 season **S**
- 1908-09-16: Tdap vaccine **S**

## Family history

- mother: Died in Malden, West Virginia, in 1876 (other accounts give 1874); cause not recorded in the cited source **D** (CLM-0003)

## Measurements

Sodium: 139 mmol/L; Potassium: 4.4 mmol/L; Bicarbonate (total CO2): 21 mmol/L (low); BUN: 34 mg/dL (high); Creatinine: 2.1 mg/dL (high); eGFR: 36 mL/min/1.73 m² (low); Glucose: 92 mg/dL; Calcium: 9.1 mg/dL; Phosphate: 4.2 mg/dL; Intact PTH: 92 pg/mL (high); Hemoglobin: 12.6 g/dL (low); Ferritin: 210 ng/mL; Transferrin saturation: 26%; TSH: 1.8 mIU/L; HbA1c: 5.4%; LDL cholesterol: 138 mg/dL (high); Urine albumin-creatinine ratio: 820 mg/g (high); PHQ-9: 4. All results are synthetic.

BP 212/128 mmHg; pulse 88 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 97% on room air; weight 71 kg; BMI 24.6 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, oriented, articulate; reports slower concentration than before, without focal neurologic deficits; Mood steady; PHQ-9 below the depression threshold. Functional status: Independent in all activities of daily living; tires more quickly and has cut back from full workdays; Finds he must prepare speeches in full and no longer trusts himself to speak impromptu. Physical examination is intentionally limited. **S**

## Assessment

1. Severe hypertension with hypertensive kidney disease; synthetic modern diagnosis linked to the documented 1804 blood pressure of 220/150; status draft. **S**
2. Chronic kidney disease stage G3b A3 (severely increased albuminuria), attributed to hypertensive nephrosclerosis; status draft. **S**
3. Hypertensive retinopathy, both eyes, without papilledema; status draft. **S**
4. Mild anemia of chronic kidney disease, iron replete; monitor; status draft. **S**
5. Hyperlipidemia; status draft. **S**

## Plan

- Treat severe hypertension without acute target-organ damage as an outpatient: start losartan and amlodipine together, check home blood pressure twice daily, and go to the emergency department for chest pain, shortness of breath, weakness, confusion, or vision loss. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025) **S**
- Nephrology referral for eGFR below 60 with severely increased albuminuria (UACR above 300 mg/g) and stage 2 hypertension. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026) **S**
- Titrate losartan to the maximum tolerated dose and add an SGLT2 inhibitor for CKD with UACR of at least 200 mg/g; accept a creatinine rise of up to 30 percent. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021) **S**
- Check potassium and creatinine one to four weeks after each renin-angiotensin, SGLT2 inhibitor, or diuretic change; then eGFR and UACR about three times a year for G3b A3, hemoglobin at least yearly, and calcium, phosphate, and PTH every six to twelve months; recalculate the kidney failure risk yearly. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026) **S**
- Moderate-intensity statin for an adult aged 50 or older with eGFR below 60; no routine repeat LDL. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026) **S**
- Sodium below 2 g a day with a plan for meals while traveling; at least 150 minutes of activity a week. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024) **S**
- Annual dilated eye examination for hypertensive retinopathy; pneumococcal and hepatitis B vaccination for chronic kidney disease. Guideline: CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026) **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (KDIGO)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (KDIGO)
- CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026), Aether Forge
